Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NHS Blood and Transplant

- PMLiVE

NHS rolls out artificial pancreas for adults and children with type 1 diabetes in England

Type 1 diabetes accounts for approximately 10% of all diabetes cases in the UK

- PMLiVE

Sanofi’s Rezurock fast-tracked by NHS for rare chronic graft versus host disease

Around 400 stem cell or bone marrow transplant patients will develop the condition each year in England

- PMLiVE

AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients

The roll out follows NICE’s recommendation of the treatment in October 2023

EU flag

EC approves Vertex/CRISPR’s Casgevy gene therapy for inherited blood disorders

There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy

- PMLiVE

UK government approves digital pathology for cancer screening programmes

The approval follows a study that showed digital pathology was as effective as microscopy

- PMLiVE

UK national study supports whole genome sequencing in standard cancer care

The trial combined data from the UK’s 100,000 Genomes Project and NHS records

EU flag

CHMP recommends gene therapy for beta thalassemia and sickle cell disease

If approved, Casgevy will be the only genetic therapy in the EU to treat these conditions

- PMLiVE

FDA approves two cell-based gene therapies for sickle cell disease

Vertex/CRISPR and bluebird bio’s gene therapies have been approved to treat patients aged 12 years and older

- PMLiVE

NHS to offer stem cell transplants to patients living with rare blood disorder

Over 600 adults in the UK are affected by transfusion-dependant thalassaemia

- PMLiVE

New report reveals antibiotic underdosing could be leading cause of AMR in UK

AMR has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

Landmark UK medicines deal to save NHS £14bn in medicine costs

The agreement will help provide lifesaving treatments and care for NHS patients

- PMLiVE

MHRA authorises world-first gene therapy for two inherited blood disorders

Casgevy is now the first licensed treatment that uses the gene-editing tool CRISPR

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links